![](/img/cover-not-exists.png)
Cost Effectiveness of Tofacitinib as Second Line Treatment Vs Using Biological Therapies In The Treatment of Moderate Rheumatoid Arthritis After Failure of Dmards In Guatemala In 2014
M. Garita-aguilar, M. Peralta-acon, N. Chavez-perezYear:
2015
Language:
english
DOI:
10.1016/j.jval.2015.03.943
File:
PDF, 50 KB
english, 2015